APEX-STROKE Adaptive Platform Trial for Stroke

Brief summary (registry, in English)

Stroke remains one of the leading causes of death and disability, worldwide. Despite advances in stroke management, only a limited number of acute treatments-including thrombolysis, endovascular thrombectomy, hemicraniectomy, stroke unit care, and aspirin-have demonstrated clear benefit, highlighting the need for widely applicable interventions that improve outcomes. Although randomized controlled trials remain the most reliable method for evaluating treatment efficacy, conventional designs typically assess a single intervention under fixed assumptions and are often costly, resource-intensive, and time-consuming. Platform trials offer a more efficient alternative by enabling the simultaneous evaluation of multiple interventions and the ongoing addition or removal of treatment arms, thereby providing a promising approach to accelerate the identification of effective therapies and transform stroke clinical research. The overarching objective of APEX-STROKE is to identify the treatment/s associated with the highest chance of improving relevant patient outcomes in stroke.

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 20000
• From 1 Sept 2026 to the primary completion date, 30 Jun 2029
• No sites listed in no country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov